NVAX is at the bottom of the fib channel right now with stochastic at interesting levels. I'm bullish and buying Jan calls with strikes $80 and up.
BMY is presently in a wedge. Though a breakdown is certainly possible over the next decade, what are reasonable breakout levels to watch? This chart with Fib levels induced by the move from all-time lows to all-time highs gives some clues. Approximately $75 is first up, then approximately $120.
Price may dip as far as the high $110s before reversing, if this channel holds. The present sell-off is induced by the tightening Fed policy amid persistently high inflation and the crypto selloff of late 2021, early 2022. 2021 also saw an avalanche of insider selling.
Humanigen's stock has two lower trend resistance lines with price targets of $3 and $2, respectively. The first resistance line has just hit after a month of major events. Catalyst 1: Marc Bistricer of Murchison and Nomis Bay bought back in after major selling over the past year. Catalyst 2: 7 corporate insiders including the CEO (Cameron Durrant) and Chief...
This chart shows bitcoin in USD versus the front-month continuous contract of the S&P 500 futures. As you can see, price is in a large, ascending wedge. A break to the downside is typical in such patterns. The green line marks where the fall might stop, approximately 70% lower that today. This would occur through a coinciding bull market in US large caps and...
HGEN has two RCTs with imminent data, one of them the company's own, the other the NIH's ACTIV-5 Trial. The company is preparing to file an EUA for Lenzilumab pending the trials' completion. Announcements are expected in the week starting March 29, two days from now. Nomis Bay, a fund that had held a large stake of HGEN since it was trading in single digits...
Morningstar says that Apple is above "fair value" and the 50 week ema lies below trend support. But the tech selloff is hurting companies vulnerable to inflation and rising credit yields. Apple is neither. Likewise, Apple is relatively invulnerable to the Biden tax plan. Watch for reclaim of the 21 week ema for confirmation of this small bounce off of trend...
OXY is punching through trends and has breached the 21 week ema. It wants the 50 week ema now. That will put it in a descending wedge which it may subsequently break out of to the upside after a period of consolidation, seeking the 100 week ema.
Stock wants to test the 50 week ema and the long-term trend line near it.
Value is the new momentum Bullish crossovers, bullish breakouts Rising yields, inflation, forced contractionary policy on the horizon, Nasdaq correction The future looks bright
On March 12: Unusual options activity 23,436 call options bought the $17 strike, expiring 4/16/2021. Open interest on those calls was 544.
Retracement to the 50 ema seems likely. In the last big bouts of yield volatility in 2016 and 2018 we went further. Tech is in for trouble, IMO.
Macerich has formed a large cup and handle. Look for an upside move beyond the old dashed resistance line and into the descending channel, which it broken out of during the corona crash. OTM call volume exceeded open interest by a large factor on Tuesday, March 9.
Tesla is still levitating far above the monthly 21-period ema, a level that stocks tend to oscillate around. The current dip has it sitting on the 9-period ema. Long-term monthly trend lines on monthly candles show that there is a lot of room to the downside of the ascending wedge the stock is in, although a $2000+ price target isn't unwarranted. Just some...
This is right before the expiration of the share lock-up for insiders. Bearishness has reached near-euphoria. A yoga teacher asked me about buying DASH puts last night. I think there's a chance we bounce at this trend support and simply slide sideways into the megaphone and wedge formed by trendiness, instead of falling down into the pit as the rest of the world...
NVDA has broken up through a very long-term resistance line (in black), and appears ready to enter into the orange wedge on recent headlines of a chip shortage, encouraging earnings, and very rosy projections for the firm's future in AI and robotics. A still-bullish but more conservative scenario is a rejection below the long-term upper resistance in black,...
ARKK is selling off harder than the market this week. It's being attributed to liquidity issues and fund outflows. But technically speaking, the issue is that the ETF is simply correcting back into longer-term channels. Where to go from here? In the past few years, ARKK has rallied well when the RSI(7) exits oversold conditions the second time in a row. And it...
Mid-March presentations of trial results are imminent. Price targets between $30 and $34 have been set. Today, RSI is testing a level that has recently held.